Comparing vaginal and buccal misoprostol when used after methotrexate for early abortion.
OBJECTIVE
The primary objective of this study was to determine if buccal misoprostol was as effective as vaginal misoprostol in medical abortions. The secondary objectives were to compare side effects and acceptability.


METHODS
This was a randomized controlled trial of 600 microg misoprostol by the buccal or vaginal routes used 3 to 6 days after 50 mg/m2 methotrexate. The participants were women presenting for abortion at 49 days or less gestation. The outcome measures were the number of women who had aborted by Day 8, side effects and acceptability.


RESULTS
Day 8 completion rate was 53.5% for the buccal route and 67.5% for the vaginal route (p = 0.012). Side effects were similar in the two groups except that there was more burning with the buccal route. Overall acceptability and route acceptability were similar in the two groups.


CONCLUSIONS
When used after methotrexate for early abortion, the vaginal route for misoprostol is more effective and preferred to the buccal route.
Wiebe
Ellen R
ER
Department of Family Practice, University of British Columbia, 1013-750 West Broadway, Vancouver, British Columbia, V5Z 1H9, Canada. ellenwiebe@telus.net
Trouton
Konia
K
D000020:Abortifacient Agents, Nonsteroidal / Q000008:administration & dosage*; D000028:Abortion, Induced; D000278:Administration, Buccal; D000282:Administration, Intravaginal; D000328:Adult; D005260:Female; D005865:Gestational Age; D006801:Humans; D008727:Methotrexate / Q000008:administration & dosage*; D016595:Misoprostol / Q000008:administration & dosage*; D011247:Pregnancy; D016896:Treatment Outcome
D000020:Abortifacient Agents, Nonsteroidal; D016595:Misoprostol; D008727:Methotrexate